Nasdaq
$2.32▲ 3.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $147.8MShares out 63.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 1d agoAfter-hours26.10.24 05:058-KKey event#●●●#●●●#●●●
MACROGENICS INCBullish
MacroGenics announced positive interim Phase 1 results for its B7-H3-directed ADC, MGC026, showing a 27% objective response rate in heavily pretreated patients with recurrent/metastatic SCCHN. The company plans to initiate a front-line combination study with pembrolizumab in early 2027.…more
$2.32+3.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:16144Ownership
MACROGENICS INC
Karen Jean Ferrante, an executive at MacroGenics Inc, has filed Form 144 regarding the proposed sale of company securities. This filing serves as a standard notification of an insider's plan to dispose of shares.…more
$2.32+3.55%vs prev closeView filingShare - 10.7After-hours26.10.08 05:224Ownership
MACROGENICS INC
MacroGenics insider Ezio Bonvini reported changes in beneficial ownership of securities effective October 6, 2026. This filing serves as a standard Form 4 notification regarding insider equity transactions.…more
$2.32+3.55%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:15#●●●#●●●
MacroGenics Reports Positive Phase 1 Interim Data for MGC026
MacroGenics announced positive interim Phase 1 results for its ADC candidate MGC026, demonstrating clinical activity and a manageable safety profile in patients with advanced solid tumors. The company plans to initiate a combination study with pembrolizumab for front-line head and neck cancer patients in early 2027.…more
$2.32+3.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15After-hours26.10.16 05:05
●●●●●●●● ●●●●● ●●●●●●
MacroGenics has initiated the first patient dosing in a Phase 1 clinical trial for its solid tumor therapeutic candidate, MGC030. The study is designed to evaluate the safety and preliminary antitumor activity of this early-stage drug candidate.…more
$2.32+3.55%vs prev close - 9.9After-hours26.09.10 05:05
●●●●●●●● ●●●●● ●●●●●●
MacroGenics announced that its CEO will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. This event participation is a standard corporate update and does not provide immediate material impact on stock performance.…more
$2.32+3.55%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report